Work

PrE0807 phase Ib feasibility trial of neoadjuvant nivolumab (N)/lirilumab (L) in cisplatin-ineligible muscle-invasive bladder cancer (BC).

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.tps4594

Authors: Petros Grivas, Maneka Puligandla, Suzanne Cole, Kevin Dale Courtney, Robert Dreicer, Benjamin Adam Gartrell, Jeremy Paul Cetnar, Marc Dall'era, Matt D. Galsky, Rohit K. Jain, Benjamin Louis Maughan, Neeraj Agarwal, Vadim S Koshkin, Noah M. Hahn, Michael Anthony Carducci

Institutions: University of Washington, Dana-Farber Cancer Institute, The University of Texas Southwestern Medical Center, University of Virginia, Albert Einstein College of Medicine, Montefiore Medical Center, Oregon Health & Science University, UC Davis Comprehensive Cancer Center, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Moffitt Cancer Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, University of Utah, Huntsman Cancer Institute, University of California, San Francisco

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2947029479

Cites:

Cited by: 3

Related to: 10